In a 6,000-patient study, Eskenazi Health will assess whether PGx testing improves outcomes and saves money in a community that doesn't usually have access to genomic advances.
The partners will focus on early treatment and diagnosis of cancers in women's health and abdominal and blood cancers.
The company said the proceeds will be used to refine its core technology and improve manufacturing.
The test, which detects various bacterial species in fecal samples, is expected to be submitted to US regulators before the end of this year.
The assays use specimens from symptomatic patients for the qualitative detection and differentiation of HSV-1 and HSV-2 with results generated within one hour.
In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.
Hong Kong is using DNA phenotyping to shame litterers.
A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.
NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.